On June 5, 2026, the FDA cleared two related products from Assure Tech., LLC of Wilmington, Delaware under 510(k) premarket notification number K260754: the Fastep COVID-19 Antigen Pen Home Test and the Fastep COVID-19 Antigen Pen Test. In the agency's taxonomy these are Class II microbiology devices, product code QYT, regulation 866.3984 — the classification for an over-the-counter COVID-19 antigen test. On a clearance list dominated by surgical instruments, imaging systems, and hospital monitors, this is the rare entry built for a consumer to hold in their own hand, in their own bathroom, with no clinician anywhere in the loop.
That last detail is the whole significance. The phrase "over-the-counter" in a 510(k) record is not a small label. It means the FDA evaluated the device for use by an untrained layperson and found it could be performed and interpreted safely without professional supervision. A test cleared for clinical use is one thing; a test cleared for a worried parent at 11 p.m. is a meaningfully harder bar. Everything about the device — the instructions, the sampling method, the readout — has to survive contact with a user who has no medical training and is, by definition, not feeling well.
The pen format and why form factor matters
The naming convention here is itself a product decision. Calling it a "Pen" test signals a form factor designed for the consumer rather than the lab: something self-contained, intuitive, and shaped like an object people already know how to hold. The lateral-flow antigen test became a household object during the pandemic precisely because its form factor collapsed a laboratory procedure into a few consumer-legible steps. Each refinement of that form — a cassette, a tube, a pen — is an attempt to shave friction off the moment of use. In consumer hardware, the industrial design of a self-test is not cosmetic; it is the difference between a test people can actually run correctly and one they botch.
The K260754 record lists an extensive set of registration and FEI numbers under its openFDA metadata, the kind of manufacturing-establishment footprint typical of a diagnostics company that produces at consumer scale. Antigen self-tests are a volume business. They are cheap per unit, sold in multipacks, stocked at the pharmacy counter, and used once and thrown away. That economics shapes everything: the device has to be manufacturable by the tens of millions, shelf-stable, and idiot-proof, because the support cost of a confused consumer dwarfs the margin on a single test.
What clearance means for a consumer diagnostic
The decision code on the record is SESE — substantially equivalent — and the clearance type is Traditional. As with any 510(k), this is a determination that the Fastep test is comparable in intended use and safety to a predicate antigen test already on the market, not an independent verdict of accuracy from scratch. For an over-the-counter diagnostic, the predicate framework does a lot of quiet work: it lets a new manufacturer enter a well-characterized category — home COVID antigen testing — without re-litigating the basic science, while still proving its specific device performs comparably.
For the consumer, the practical meaning is trust calibration. A cleared antigen self-test is held to the same regulatory category as its competitors on the shelf, which is the assurance the QYT product code is meant to convey. It is also a reminder of what antigen tests are and are not: they are fast and convenient but less sensitive than laboratory PCR, which is why the instructions for these devices typically advise serial testing and why a negative result is a snapshot, not a guarantee. None of that is in the K-number, but all of it is implied by the category the K-number files the device into.
There is a deeper structural point in the timing of this clearance. The home antigen test was forged in the emergency of a pandemic, much of it under emergency-use authorizations rather than full clearances. A standard 510(k) clearance in 2026 — through the Traditional pathway, against an established predicate, under a settled product-code regulation — signals that the category has matured out of crisis mode and into a normal, durable consumer-diagnostics market. The regulatory framework that once had to be improvised under pressure is now routine, and a manufacturer can enter it the ordinary way. That normalization is itself the news. The home self-test is no longer an emergency measure; it is a permanent fixture of the medicine cabinet with a stable regulatory home, and clearances like K260754 are what keep populating the shelf as the early pandemic-era authorizations age out.
The consumer-tech angle
The at-home antigen test is one of the clearest examples of a medical capability migrating into a consumer product. A measurement that once required a clinic visit — am I infectious right now? — became something you buy in a box and run yourself. That migration is the same pattern playing out across consumer health hardware: continuous monitors moving from the hospital to the wrist, imaging AI moving from the radiology suite to the cloud, and diagnostics moving from the lab to the medicine cabinet. The self-test got there first and most completely, because a single-use chemical assay is easier to put in a consumer's hands than a regulated wearable or an autonomous AI.
What keeps a consumer diagnostic honest is exactly the record we just read. Anyone can sell a strip that changes color; only a cleared device can sell it as an over-the-counter COVID-19 antigen test with the regulatory weight that phrase carries. K260754 is the entry that lets Assure Tech put "FDA-cleared" on the box, and on a clearance list otherwise full of professional hardware, it is a useful reminder of where this entire category is heading: toward the consumer, one cleared self-test at a time. The pen is a small object. The clearance behind it is the reason it can sit on a shelf and be trusted.